Report contents
At a glance
- Johnson & Johnson earns most of its profit from patent-protected Innovative Medicine, with MedTech adding slower device sales. The clinical switching costs are real at the point of care, but they do not give it power over payers. The obstacle is replacing Stelara, about $10.4 billion of 2024 sales, without ceding gross margin.
- Operating cash flow has held at $21.2–24.5 billion and free cash flow at $17.2–19.8 billion over five years, while the September 2026 charge cut net income without touching cash. Net debt of $27.7 billion is manageable against $81.5 billion of equity, and interest costs remain low. Liquidity is thinner than the leverage ratios suggest, so distributions depend on non-cash charges.
Business model
Business model: one profit engine inside two reporting segments
J&J reports two segments, and they behave nothing alike. Innovative Medicine, with $57.0 billion of the $88.8 billion in FY2024 sales the company reported, sells prescription drugs for immunology, oncology, neuroscience and pulmonary hypertension. MedTech, at $31.9 billion, sells surgical staplers and energy devices, orthopaedic implants, electrophysiology catheters and vision products. Revenue looks roughly balanced at two to one. Profit does not.
The payer sits between J&J and the patient
The person choosing a J&J product is a physician or a surgeon. The person paying is usually someone else. In the US, commercial insurers and their pharmacy benefit managers, plus Medicare and Medicaid, fund the drugs; hospitals and ambulatory surgery centers fund the devices, often through group purchasing organizations (GPOs) that pool purchases and set a de facto price ceiling. Outside the US, national health systems decide formulary access and run tenders. J&J sets a list price and collects less after rebates and discounts, which is why management talks about net price: US list prices routinely rise faster than net revenue.
That structure explains the economics. A drug carries high gross margin and concentrates its cost in R&D, about $17 billion in 2024 and roughly a fifth of sales; once approved, the marginal cost of the next prescription is small. A device needs a plant, inventory, and sales representatives in the operating room, and it faces buyers who can credibly consolidate volume onto a rival. MedTech converts a visibly smaller share of its sales into segment profit than Innovative Medicine, and its pricing is renegotiated every contract cycle. The pharma side funds the group; the device side supplies diversification and a slower growth rate.
A patent cliff, not a demand problem
Concentration is the clearest fragility. Darzalex produced about $11.7 billion of 2024 sales and Stelara about $10.4 billion, so two products accounted for roughly a quarter of group revenue. Stelara has lost US exclusivity and biosimilar versions began selling in 2025; the volume does not vanish at once, but the price does. J&J's answer is a portfolio: Tremfya in immunology, Darzalex and Carvykti in myeloma, Rybrevant with Lazcluze in lung cancer, Spravato in depression, and electrophysiology and heart-failure devices on the MedTech side. Whether that bundle grows faster than the Stelara hole is the operating question behind every forecast.
Mix matters to how it resolves. Because Innovative Medicine earns most of the profit, a drug shortfall hits earnings harder than its revenue share implies. MedTech is the slower, more capital-intensive half, and it is being reshaped: Kenvue, the consumer health business, was separated in May 2024, and in October 2025 the company said it planned to separate DePuy Synthes, its orthopaedics business, within 18 to 24 months. That would leave a portfolio tilted toward higher-growth device franchises and reduce exposure to commodity implants, where J&J is one of several large suppliers.
Bargaining power is clinical, not commercial
J&J's leverage comes from being hard to replace at the point of care: an implant a surgeon trained on, a drug with a label no rival matches. That advantage is real but narrow. It does not extend to the payer, and it is being tested. Stelara and Xarelto were both selected in Medicare's first round of drug price negotiation, with negotiated prices effective January 1, 2026, which moves more of the price conversation to the government. In devices, hospital consolidation and China's volume-based procurement program have already pushed down prices on standard implants. What survives is differentiation: pulsed field ablation catheters, CAR-T, robotics. The base portfolio does not have it.
Stage, and the test that would overturn this
J&J is a mature, research-driven manufacturer in transition. After Kenvue, and with orthopaedics on the way out, "conglomerate" no longer describes it. The business needs roughly $17 billion of annual R&D plus serial acquisitions to refill a portfolio that loses exclusivity on a schedule. That is a treadmill, not a moat, and what matters is whether new products replace old ones at comparable margins.
Two disclosure limits matter. J&J reports segment sales and segment pretax profit but not R&D or marketing by segment, so the cost of refilling the drug portfolio cannot be traced to the products that need it. And the talc litigation overhang, where a bankruptcy court declined to approve a subsidiary's Chapter 11 plan in March 2025 and the company has said it will defend the claims in the tort system, is a contingency rather than an operating cost until resolved; the claims remain allegations.
The judgment above would be wrong if the growth products sustain combined double-digit growth through the Stelara erosion without gross margin slipping, or if MedTech's differentiated franchises hold price while hospital buyers consolidate. Either outcome would show that clinical switching costs outlast payer pressure for longer than the current portfolio cycle implies.
Questions worth following
- Can J&J's newer drugs replace Stelara's eroding sales?
Stelara was roughly $10 billion of annual revenue and now faces biosimilar competition. Whether Tremfya, Darzalex, Carvykti and Rybrevant grow faster than that decline determines group revenue, gross margin, and how much acquisition spending J&J needs to refill the portfolio.
- Will MedTech pricing hold as hospital buyers consolidate?
MedTech earns thinner segment profit than drugs and sells to buyers who pool purchases through GPOs and government tenders. Holding realized device pricing would let MedTech add revenue without repeating the drug portfolio's cliff risk; erosion would leave the group even more dependent on pharmaceuticals.
- Can J&J separate DePuy Synthes without losing MedTech scale?
Orthopaedics is J&J's slowest-growing device unit, and carving it out should leave a faster portfolio. The risk sits in dis-synergies: shared manufacturing, hospital contracts and back-office costs now spread across MedTech. Cost leakage or management distraction would offset the strategic gain.
Financial quality
Financial quality: cash is steadier than the earnings line
J&J earns high returns from a stable operating base, and it has produced $17–20 billion of free cash flow in each of the last five fiscal years. Reported net income tells a far wilder story: $35.2 billion in FY2023, $14.1 billion in FY2024, $26.8 billion in FY2025 and $0.21 billion in the quarter ended September 30, 2026. The distance between those two records is the central fact about the quality of these earnings.
Operating margin holds; the lines below it do not
Gross margin has stayed between 67.9% and 70.3% since FY2021, and operating margin between 24.9% and 27.2%. That is the durable core: roughly 68 cents of gross profit per revenue dollar, about 41 points of selling, research and administrative cost, and a quarter of sales left at the operating line. The September 2026 quarter fit the pattern, with $25.4 billion of revenue, $17.3 billion of gross profit and $5.85 billion of operating income.
Below the operating line, the numbers break pattern. That quarter's EBIT was $0.25 billion against operating income of $5.85 billion, and the tax provision was a credit of $0.18 billion, leaving net income at $0.21 billion. The arithmetic implies roughly $5.6 billion of non-operating charges and a tax benefit attached to them. The same distortion runs in the opposite direction in FY2025's first quarter ($11.0 billion of net income on $6.3 billion of operating income) and in FY2023 ($35.2 billion of net income on $21.9 billion of operating income).
Return on equity therefore misleads in both directions: 48.3% in FY2023 and 20.1% in FY2024 reflect one-time items, not a change in capital efficiency. An estimate based on reported figures is more useful. At the end of FY2025, equity of $81.5 billion plus total debt of $47.9 billion less cash of $19.7 billion gives about $110 billion of invested capital; after-tax operating profit of roughly $21 billion on that base implies an ROIC near 19%. Goodwill of $48.8 billion is about 44% of that capital, so returns on the operating assets themselves are higher still.
Annual financial metrics
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | Q3 FY2026 (3M) | Assessment |
|---|---|---|---|---|---|---|---|
| Revenue (USD bn) | 78.74 | 79.99 | 85.16 | 88.82 | 94.19 | 25.40 | Adequate, mid-single-digit |
| Gross margin (%) | 70.3 | 69.3 | 68.6 | 69.1 | 67.9 | 68.1 | Strong for pharma |
| Operating margin (%) | 26.6 | 26.3 | 25.7 | 24.9 | 27.2 | 23.0 | Strong, stable |
| Net margin (%) | 26.5 | 22.4 | 41.3 | 15.8 | 28.5 | 0.8 | Distorted by one-time items |
| ROE (%) | 30.4 | 23.8 | 48.3 | 20.1 | 35.0 | 0.25 (quarterly) | Strong but flattered |
| ROA (%) | 11.7 | 9.7 | 19.8 | 8.1 | 14.1 | 0.1 | Strong |
| Total liabilities/assets (%) | 59.3 | 59.0 | 59.1 | 60.3 | 59.1 | 58.7 | Adequate, stable |
| Current ratio | 1.35 | 0.99 | 1.16 | 1.11 | 1.03 | 1.02 | Thin |
| Quick ratio | 1.12 | 0.81 | 0.91 | 0.86 | 0.77 | 0.74 | Middling |
| Asset turnover (x) | 0.44 | 0.43 | 0.48 | 0.51 | 0.50 | 0.13 (quarterly) | Typical with large goodwill |
| Inventory turnover (x) | 2.37 | 2.38 | 2.49 | 2.33 | 2.27 | 0.53 (quarterly) | Adequate |
| Receivables turnover (x) | 4.84 | 4.46 | 5.36 | 5.26 | 5.22 | 1.34 (quarterly) | Adequate, ~70 days |
| Operating cash flow (USD bn) | 23.41 | 21.19 | 22.79 | 24.27 | 24.53 | 7.72 | Strong |
| Capex (USD bn) | 3.65 | 4.01 | 4.54 | 4.43 | 4.83 | 1.36 | Asset-light, ~5% of revenue |
| Free cash flow (USD bn) | 19.76 | 17.18 | 18.25 | 19.84 | 19.70 | 6.36 | Strong |
| Operating cash flow/net income (x) | 1.12 | 1.18 | 0.65 | 1.73 | 0.92 | 36.8 | Noisy, but cash-backed |
Cash conversion: the charge cost earnings, not cash
Operating cash flow of $7.72 billion in the September 2026 quarter, less $1.36 billion of capex, produced $6.36 billion of free cash flow against net income of $0.21 billion. The charge landed on earnings, not on the bank balance. Over five years, operating cash flow has ranged $21.2–24.5 billion, capex has held at 4.6–5.3% of revenue, and free cash flow has ranged $17.2–19.8 billion. The operating cash flow/net income ratio swung from 0.65x in FY2023, when a gain inflated the denominator, to 1.73x in FY2024, when charges depressed it. Both series point to the same conclusion: about $20 billion of annual cash, and an earnings figure that depends on which legal item landed in the period.
Working capital shows no strain. Receivables run near 70 days and quarterly turnover has sat around 1.35x for seven straight quarters. Inventory turns 2.27x a year, about 160 days, and the $15.4 billion balance at September 2026 was up roughly 8% from $14.2 billion at end-2025, in line with nine-month revenue growth near 7%.
Quarterly progression
| Period | Revenue (USD bn) | Gross margin (%) | Net margin (%) | Total assets (USD bn) | Liabilities (USD bn) | Net PP&E (USD bn) | OCF (USD bn) | FCF (USD bn) | Current ratio | Assessment | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q1 FY2025 | 21.89 | 66.4 | 50.2 | 193.67 | 115.56 | 20.87 | 4.17 | 3.38 | 1.26 | Inflated by a gain | Nonrecurring |
| Q2 FY2025 | 23.74 | 67.9 | 23.3 | 193.39 | 114.92 | 21.95 | 3.88 | 2.48 | 1.01 | Clean quarter | Stable |
| Q3 FY2025 | 23.99 | 69.6 | 21.5 | 192.82 | 113.54 | 22.34 | 9.17 | 8.38 | 1.07 | Normal | Stable |
| Q4 FY2025 | 24.56 | 67.6 | 20.8 | 199.21 | 117.67 | 24.47 | 7.31 | 5.47 | 1.03 | Normal | Stable |
| Q1 FY2026 | 24.06 | 66.3 | 21.8 | 200.89 | 119.71 | Not disclosed | 2.51 | 1.47 | 1.03 | Normal | Stable |
| Q2 FY2026 | 25.31 | 68.2 | 21.9 | 201.06 | 116.09 | Not disclosed | 8.62 | 7.29 | 1.09 | Normal | Stable |
| Q3 FY2026 | 25.40 | 68.1 | 0.8 | 197.43 | 115.90 | Not disclosed | 7.72 | 6.36 | 1.02 | Hit by a large charge | Weaker reported earnings only |
Leverage is comfortable, liquidity is tighter than it looks
Liabilities of 58.7% of assets look demanding for a company relying on litigation-sensitive products, but interest expense was $0.97 billion in FY2025 on roughly $48 billion of debt, an average cost near 2%, and free cash flow covers it many times over. The current ratio of 1.02 and quick ratio of 0.74 are the tighter part: $56.4 billion of current assets against $55.5 billion of current liabilities, with $16.9 billion of cash. Debt has risen to $44.7 billion from $36.6 billion at the end of 2024 while cash fell from $24.1 billion to $16.9 billion, and financing outflows of $8.8 billion and $8.5 billion in the June and September 2026 quarters exceeded free cash flow of $7.3 billion and $6.4 billion. Equity fell $3.4 billion in the September quarter. That is not a solvency problem at this level of cash generation, but it means distributions depend on charges staying non-cash.
What to check
- The size and recurrence of the September 2026 charge. The gap between $5.85 billion of operating income and $0.21 billion of net income, together with the tax credit, needs to be matched against disclosed reserves. If the reserve absorbs the item without new charges, net margin recovers; a similar charge each quarter would keep it near zero.
- Goodwill of $48.5 billion, about 59% of equity. Impairment testing headroom matters because the current ROIC depends on that capital base. A writedown would not touch cash but would cut book value and reported returns.
- Distributions against free cash flow. Two consecutive quarters of financing outflow above free cash flow, funded partly from a lower cash balance, is worth tracking alongside any further debt issuance and its coupon.
Generated by DeepVal AI. Data and models may contain errors or be outdated. For research only; not personalized investment advice.
Continue reading the full report
- Key risksWhat could break the investment case
- Valuation and margin of safetyWhat the current price assumes, and how much room for error it leaves
- SummaryOur overall judgement and what to watch next
Free to sign up · 20 research points · unlocking this report uses 10
20 points cover 2 full reports. No card needed.
Research reflects its generation date. Preview the first two modules.
More on Johnson & Johnson
Johnson & Johnson
Business, moat and key questions
Open company page